CUREator by Brandon BioCatalyst has announced the deployment of $7.21 million in funding to support eight biotech companies across its Clinical and Preclinical streams thanks to the Federal Government’s Medical Research Future Fund’s Early-Stage Translation and Commercialisation Support (ESTAC) grant.
This latest round of the competitive commercial grant funding program will allocate $5.84 million to five clinical-stage companies, including Respirion Pharmaceuticals. This funding will enable the companies to explore the efficacy of novel drugs or innovative applications for existing medications.
Click here to read the full Media Release from Brandon BioCatalyst (Brandon Capital).
